{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T22:00:07Z","timestamp":1785362407701,"version":"3.55.0"},"reference-count":106,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Laboratory Medicine"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.cll.2026.06.005","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T21:17:42Z","timestamp":1785359862000},"page":"479-499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["This is Your Thyroid on Drugs"],"prefix":"10.1016","volume":"46","author":[{"given":"Ying-Hsia","family":"Chu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cll.2026.06.005_bib1","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1089\/thy.2021.0662","article-title":"Thyroid cancer incidence and mortality trends in the United States: 2000-2018","volume":"32","author":"Megwalu","year":"2022","journal-title":"Thyroid"},{"issue":"13","key":"10.1016\/j.cll.2026.06.005_bib2","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1001\/jama.2017.2719","article-title":"Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974-2013","volume":"317","author":"Lim","year":"2017","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.cll.2026.06.005_bib3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/thy.2018.0597","volume":"29","author":"Tuttle","year":"2019","journal-title":"Thyroid"},{"issue":"8","key":"10.1016\/j.cll.2026.06.005_bib4","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/jc.2005-2838","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.cll.2026.06.005_bib5","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1089\/thy.2020.0668","article-title":"Papillary thyroid carcinoma with high-grade features versus poorly differentiated thyroid carcinoma: an analysis of clinicopathologic and molecular features and outcome","volume":"31","author":"Wong","year":"2021","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.cll.2026.06.005_bib6","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1210\/jc.2013-3842","article-title":"Outcomes in patients with poorly differentiated thyroid carcinoma","volume":"99","author":"Ibrahimpasic","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.cll.2026.06.005_bib7","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","year":"2014","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.cll.2026.06.005_bib8","doi-asserted-by":"crossref","first-page":"e1006239","DOI":"10.1371\/journal.pgen.1006239","article-title":"Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers","volume":"12","author":"Yoo","year":"2016","journal-title":"PLoS Genet"},{"issue":"12","key":"10.1016\/j.cll.2026.06.005_bib9","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1089\/thy.2019.0802","article-title":"RET, NTRK, ALK, BRAF, and MET Fusions in a large cohort of pediatric papillary thyroid carcinomas","volume":"30","author":"Pekova","year":"2020","journal-title":"Thyroid"},{"issue":"6543","key":"10.1016\/j.cll.2026.06.005_bib10","doi-asserted-by":"crossref","first-page":"eabg2538","DOI":"10.1126\/science.abg2538","article-title":"Radiation-related genomic profile of papillary thyroid carcinoma after the Chernobyl accident","volume":"372","author":"Morton","year":"2021","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.cll.2026.06.005_bib11","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1038\/s41379-020-0638-5","article-title":"Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization","volume":"33","author":"Chu","year":"2020","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.cll.2026.06.005_bib12","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1634\/theoncologist.2016-0279","article-title":"pediatric, adolescent, and young adult thyroid carcinoma harbors frequent and diverse targetable genomic alterations, including kinase fusions","volume":"22","author":"Vanden Borre","year":"2017","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.cll.2026.06.005_bib13","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/cncy.22522","article-title":"NTRK-rearranged papillary thyroid carcinoma demonstrates frequent subtle nuclear features and indeterminate cytologic diagnoses","volume":"130","author":"Lee","year":"2022","journal-title":"Cancer Cytopathol"},{"issue":"11","key":"10.1016\/j.cll.2026.06.005_bib14","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1530\/ERC-19-0325","article-title":"Characterization of thyroid cancer driven by known and novel ALK fusions","volume":"26","author":"Panebianco","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"11","key":"10.1016\/j.cll.2026.06.005_bib15","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/cncy.22374","article-title":"Cytomorphologic features of NTRK-rearranged thyroid carcinoma","volume":"128","author":"Viswanathan","year":"2020","journal-title":"Cancer Cytopathol"},{"issue":"11","key":"10.1016\/j.cll.2026.06.005_bib16","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/cncy.22353","article-title":"Fine-needle aspiration cytomorphology of papillary thyroid carcinoma with NTRK gene rearrangement from a case series with predominantly indeterminate cytology","volume":"128","author":"Abi-Raad","year":"2020","journal-title":"Cancer Cytopathol"},{"issue":"7","key":"10.1016\/j.cll.2026.06.005_bib17","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cncr.29887","article-title":"NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States","volume":"122","author":"Prasad","year":"2016","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.cll.2026.06.005_bib18","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1007\/s12105-018-0995-2","article-title":"secretory carcinoma of the thyroid gland: report of a highly aggressive case clinically mimicking undifferentiated carcinoma and review of the literature","volume":"13","author":"Desai","year":"2019","journal-title":"Head Neck Pathol"},{"issue":"3","key":"10.1016\/j.cll.2026.06.005_bib19","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Invest"},{"issue":"13","key":"10.1016\/j.cll.2026.06.005_bib20","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.cll.2026.06.005_bib21","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1093\/hmg\/ddu749","article-title":"Characterization of the mutational landscape of anaplastic thyroid cancer via whole-exome sequencing","volume":"24","author":"Kunstman","year":"2015","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.cll.2026.06.005_bib22","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/his.14550","article-title":"Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases","volume":"80","author":"Xu","year":"2022","journal-title":"Histopathology"},{"issue":"7","key":"10.1016\/j.cll.2026.06.005_bib23","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3390\/cells9071570","article-title":"The molecular landscape of h\u00fcrthle cell thyroid cancer is associated with altered mitochondrial function-a comprehensive review","volume":"9","author":"Kumari","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.cll.2026.06.005_bib24","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ccell.2018.07.002","article-title":"Integrated genomic analysis of h\u00fcrthle cell cancer reveals oncogenic drivers, recurrent mitochondrial mutations, and unique chromosomal landscapes","volume":"34","author":"Ganly","year":"2018","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.cll.2026.06.005_bib25","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ccell.2018.06.013","article-title":"Widespread chromosomal losses and mitochondrial DNA alterations as genetic drivers in h\u00fcrthle cell carcinoma","volume":"34","author":"Gopal","year":"2018","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.cll.2026.06.005_bib26","doi-asserted-by":"crossref","first-page":"9001","DOI":"10.1073\/pnas.0703056104","article-title":"Disruptive mitochondrial DNA mutations in complex I subunits are markers of oncocytic phenotype in thyroid tumors","volume":"104","author":"Gasparre","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.cll.2026.06.005_bib27","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1073\/pnas.1811360116","article-title":"Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds","volume":"116","author":"Cruz-Migoni","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.cll.2026.06.005_bib28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/s41417-021-00383-9","article-title":"The KRAS-G12C inhibitor: activity and resistance","volume":"29","author":"Liu","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"10.1016\/j.cll.2026.06.005_bib29","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.cll.2026.06.005_bib30","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1406470","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","journal-title":"N Engl J Med"},{"issue":"9940","key":"10.1016\/j.cll.2026.06.005_bib31","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cll.2026.06.005_bib32","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2159-8290.CD-19-1116","article-title":"Advances in targeting RET-dependent cancers","volume":"10","author":"Subbiah","year":"2020","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.cll.2026.06.005_bib33","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S1470-2045(16)30166-8","article-title":"Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial","volume":"17","author":"Brose","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.cll.2026.06.005_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.cll.2026.06.005_bib35","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"issue":"7287","key":"10.1016\/j.cll.2026.06.005_bib36","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature08902","article-title":"RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF","volume":"464","author":"Poulikakos","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.cll.2026.06.005_bib37","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.3389\/fmicb.2018.01806","article-title":"The Role of Human Papillomaviruses and Polyomaviruses in BRAF-Inhibitor Induced Cutaneous Squamous Cell Carcinoma and Benign Squamoproliferative Lesions","volume":"9","author":"Purdie","year":"2018","journal-title":"Front Microbiol"},{"issue":"9","key":"10.1016\/j.cll.2026.06.005_bib38","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1089\/thy.2019.0514","article-title":"Acquired secondary RAS mutation in BRAF(V600E)-mutated thyroid cancer patients treated with BRAF inhibitors","volume":"30","author":"Cabanillas","year":"2020","journal-title":"Thyroid"},{"issue":"7","key":"10.1016\/j.cll.2026.06.005_bib39","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJMoa1209288","article-title":"Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer","volume":"368","author":"Ho","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cll.2026.06.005_bib40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1089\/thy.2021.0565","article-title":"Enhancing radioiodine incorporation in BRAF-mutant, radioiodine-refractory thyroid cancers with vemurafenib and the anti-ErbB3 monoclonal antibody CDX-3379: results of a pilot clinical trial","volume":"32","author":"Tchekmedyian","year":"2022","journal-title":"Thyroid"},{"issue":"3","key":"10.1016\/j.cll.2026.06.005_bib41","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s12020-022-03031-w","article-title":"Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma","volume":"76","author":"Qiao","year":"2022","journal-title":"Endocrine"},{"issue":"9","key":"10.1016\/j.cll.2026.06.005_bib42","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.cll.2026.06.005_bib43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.cll.2026.06.005_bib44","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.cll.2026.06.005_bib45","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1470-2045(18)30119-0","article-title":"Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study","volume":"19","author":"Laetsch","year":"2018","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.cll.2026.06.005_bib46","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1530\/EJE-21-1259","article-title":"Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma","volume":"186","author":"Waguespack","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.cll.2026.06.005_bib47","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.cll.2026.06.005_bib48","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdw042","article-title":"What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC)","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.cll.2026.06.005_bib49","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.cll.2026.06.005_bib50","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2159-8290.CD-15-0940","article-title":"Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer","volume":"6","author":"Russo","year":"2016","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.cll.2026.06.005_bib51","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1093\/annonc\/mdy539","article-title":"Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study","volume":"30","author":"Hong","year":"2019","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.cll.2026.06.005_bib52","doi-asserted-by":"crossref","first-page":"478","DOI":"10.6004\/jnccn.2021.7022","article-title":"clinical activity of selitrectinib in a patient with mammary analogue secretory carcinoma of the parotid gland with secondary resistance to entrectinib","volume":"19","author":"Florou","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"10.1016\/j.cll.2026.06.005_bib53","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1158\/1535-7163.MCT-21-0632","article-title":"Molecular characteristics of repotrectinib that enable potent inhibition of TRK fusion proteins and resistant mutations","volume":"20","author":"Murray","year":"2021","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.cll.2026.06.005_bib54","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1007\/s00268-014-2485-3","article-title":"Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target","volume":"38","author":"Demeure","year":"2014","journal-title":"World J Surg"},{"issue":"7","key":"10.1016\/j.cll.2026.06.005_bib55","doi-asserted-by":"crossref","first-page":"495","DOI":"10.5306\/wjco.v11.i7.495","article-title":"Complete response in anaplastic lymphoma kinase-rearranged oncocytic thyroid cancer: a case report and review of literature","volume":"11","author":"de Salins","year":"2020","journal-title":"World J Clin Oncol"},{"issue":"2","key":"10.1016\/j.cll.2026.06.005_bib56","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/thy.2019.0202","article-title":"Remarkable response to ceritinib and brigatinib in an anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma previously treated with crizotinib","volume":"30","author":"Leroy","year":"2020","journal-title":"Thyroid"},{"issue":"20","key":"10.1016\/j.cll.2026.06.005_bib57","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1200\/JCO.2013.49.6596","article-title":"Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma","volume":"33","author":"Godbert","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.cll.2026.06.005_bib58","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1089\/thy.2019.0041","article-title":"A novel ALK fusion in pediatric medullary thyroid carcinoma","volume":"29","author":"Hillier","year":"2019","journal-title":"Thyroid"},{"issue":"22","key":"10.1016\/j.cll.2026.06.005_bib59","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1158\/1078-0432.CCR-19-1436","article-title":"Treatment with next-generation ALK inhibitors fuels plasma ALK mutation diversity","volume":"25","author":"Dagogo-Jack","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.cll.2026.06.005_bib60","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000430852","article-title":"Updated evidence on the mechanisms of resistance to ALK inhibitors and strategies to overcome such resistance: clinical and preclinical data","volume":"38","author":"Toyokawa","year":"2015","journal-title":"Oncol Res Treat"},{"issue":"12","key":"10.1016\/j.cll.2026.06.005_bib61","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1093\/annonc\/mdt379","article-title":"A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes","volume":"24","author":"Lim","year":"2013","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.cll.2026.06.005_bib62","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1158\/1078-0432.CCR-17-2297","article-title":"Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study","volume":"24","author":"Hanna","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.cll.2026.06.005_bib63","first-page":"698","article-title":"Everolimus in patients with advanced follicular-derived thyroid cancer: results of a phase II clinical trial","volume":"102","author":"Schneider","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.cll.2026.06.005_bib64","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/cncr.22244","article-title":"Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases","volume":"107","author":"Roman","year":"2006","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.cll.2026.06.005_bib65","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3892\/ol.2010.223","article-title":"Medullary thyroid carcinoma: The third most common thyroid cancer reviewed","volume":"2","author":"Stamatakos","year":"2011","journal-title":"Oncol Lett"},{"issue":"6","key":"10.1016\/j.cll.2026.06.005_bib66","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised american thyroid association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"issue":"22","key":"10.1016\/j.cll.2026.06.005_bib67","doi-asserted-by":"crossref","first-page":"10741","DOI":"10.1158\/0008-5472.CAN-06-3329","article-title":"Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B","volume":"66","author":"Gujral","year":"2006","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.cll.2026.06.005_bib68","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/s12022-016-9449-0","article-title":"Medullary thyroid carcinoma: recent advances including MicroRNA expression","volume":"27","author":"Chu","year":"2016","journal-title":"Endocr Pathol"},{"issue":"1","key":"10.1016\/j.cll.2026.06.005_bib69","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/cncr.10205","article-title":"Medullary thyroid carcinoma as part of a multiple endocrine neoplasia type 2B syndrome: influence of the stage on the clinical course","volume":"94","author":"Leboulleux","year":"2002","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.cll.2026.06.005_bib70","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.bjc.6605056","article-title":"Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas","volume":"100","author":"Moura","year":"2009","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.cll.2026.06.005_bib71","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1210\/jc.2014-4153","article-title":"RET fusion as a novel driver of medullary thyroid carcinoma","volume":"100","author":"Grubbs","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.cll.2026.06.005_bib72","doi-asserted-by":"crossref","first-page":"a000729","DOI":"10.1101\/mcs.a000729","article-title":"Putative BRAF activating fusion in a medullary thyroid cancer","volume":"2","author":"Kasaian","year":"2016","journal-title":"Cold Spring Harb Mol Case Stud"},{"issue":"8","key":"10.1016\/j.cll.2026.06.005_bib73","doi-asserted-by":"crossref","first-page":"e1005467","DOI":"10.1371\/journal.pgen.1005467","article-title":"Identification of driving ALK fusion genes and genomic landscape of medullary thyroid cancer","volume":"11","author":"Ji","year":"2015","journal-title":"PLoS Genet"},{"issue":"2","key":"10.1016\/j.cll.2026.06.005_bib74","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Jr","year":"2012","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.cll.2026.06.005_bib75","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.cll.2026.06.005_bib76","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.cll.2026.06.005_bib77","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"2","key":"10.1016\/j.cll.2026.06.005_bib78","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"10.1016\/j.cll.2026.06.005_bib79","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1200\/JCO.2020.38.15_suppl.3616","article-title":"The next-generation RET inhibitor TPX-0046 is active in drug-resistant and na\u00efve RET-driven cancer models","volume":"38","author":"Drilon","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.cll.2026.06.005_bib80","doi-asserted-by":"crossref","first-page":"E863","DOI":"10.1210\/jc.2010-1921","article-title":"High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas","volume":"96","author":"Moura","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"D1","key":"10.1016\/j.cll.2026.06.005_bib81","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the catalogue of somatic mutations in cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"10.1016\/j.cll.2026.06.005_bib82","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"10.1016\/j.cll.2026.06.005_bib83","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1210\/jc.2010-1899","article-title":"Inhibition of the Ras\/Raf\/MEK\/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies","volume":"96","author":"Hong","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.cll.2026.06.005_bib84","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1097\/PAI.0000000000000516","article-title":"BRAF V600E mutation across multiple tumor types: correlation between DNA-based sequencing and mutation-specific immunohistochemistry","volume":"26","author":"Loo","year":"2018","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"5","key":"10.1016\/j.cll.2026.06.005_bib85","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.semdp.2015.02.010","article-title":"BRAF V600E mutation-specific antibody: a review","volume":"32","author":"Ritterhouse","year":"2015","journal-title":"Semin Diagn Pathol"},{"issue":"4","key":"10.1016\/j.cll.2026.06.005_bib86","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/his.14396","article-title":"NRAS Q61R immunohistochemical staining in thyroid pathology: sensitivity, specificity and utility","volume":"79","author":"Saliba","year":"2021","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.cll.2026.06.005_bib87","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12022-016-9466-z","article-title":"Detecting N-RAS Q61R Mutated Thyroid Neoplasias by Immunohistochemistry","volume":"28","author":"Crescenzi","year":"2017","journal-title":"Endocr Pathol"},{"issue":"1","key":"10.1016\/j.cll.2026.06.005_bib88","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","article-title":"NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls","volume":"33","author":"Solomon","year":"2020","journal-title":"Mod Pathol"},{"issue":"13","key":"10.1016\/j.cll.2026.06.005_bib89","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1158\/0008-5472.CAN-19-0372","article-title":"Detection of NTRK fusions: merits and limitations of current diagnostic platforms","volume":"79","author":"Solomon","year":"2019","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.cll.2026.06.005_bib90","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1530\/ERC-14-0467","article-title":"Standard immunohistochemistry efficiently screens for anaplastic lymphoma kinase rearrangements in differentiated thyroid cancer","volume":"22","author":"Park","year":"2015","journal-title":"Endocr Relat Cancer"},{"issue":"5","key":"10.1016\/j.cll.2026.06.005_bib91","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1097\/PAS.0000000000000368","article-title":"A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma","volume":"39","author":"Chou","year":"2015","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"10.1016\/j.cll.2026.06.005_bib92","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1158\/1078-0432.CCR-20-3208","article-title":"A performance comparison of commonly used assays to detect RET fusions","volume":"27","author":"Yang","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cll.2026.06.005_bib93","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.humpath.2020.09.004","article-title":"Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas","volume":"106","author":"Nozaki","year":"2020","journal-title":"Hum Pathol"},{"issue":"4","key":"10.1016\/j.cll.2026.06.005_bib94","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s12022-020-09648-9","article-title":"Detection of NTRK1\/3 rearrangements in papillary thyroid carcinoma using immunohistochemistry, fluorescent in situ hybridization, and next-generation sequencing","volume":"31","author":"Lee","year":"2020","journal-title":"Endocr Pathol"},{"issue":"5","key":"10.1016\/j.cll.2026.06.005_bib95","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/modpathol.2017.181","article-title":"Genomic heterogeneity of ALK fusion breakpoints in non-small-cell lung cancer","volume":"31","author":"Rosenbaum","year":"2018","journal-title":"Mod Pathol"},{"issue":"6","key":"10.1016\/j.cll.2026.06.005_bib96","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jmoldx.2022.03.006","article-title":"Clinical utility and performance of an ultrarapid multiplex RNA-based assay for detection of ALK, ROS1, RET, and NTRK1\/2\/3 rearrangements and MET exon 14 skipping alterations","volume":"24","author":"Chu","year":"2022","journal-title":"J Mol Diagn"},{"issue":"1","key":"10.1016\/j.cll.2026.06.005_bib97","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13046-018-0735-1","article-title":"5\u2019\/3\u2019 imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer","volume":"37","author":"Tong","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.cll.2026.06.005_bib98","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1111\/1759-7714.13535","article-title":"Clinical evaluation of the effectiveness of fusion-induced asymmetric transcription assay-based reverse transcription droplet digital PCR for ALK detection in formalin-fixed paraffin-embedded samples from lung cancer","volume":"11","author":"Liu","year":"2020","journal-title":"Thorac Cancer"},{"issue":"2","key":"10.1016\/j.cll.2026.06.005_bib99","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jmoldx.2013.11.007","article-title":"A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer","volume":"16","author":"Lira","year":"2014","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.cll.2026.06.005_bib100","doi-asserted-by":"crossref","first-page":"42259","DOI":"10.1038\/srep42259","article-title":"Multiplexed transcriptome analysis to detect ALK, ROS1 and RET rearrangements in lung cancer","volume":"7","author":"Rogers","year":"2017","journal-title":"Sci Rep"},{"issue":"5","key":"10.1016\/j.cll.2026.06.005_bib101","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1002\/path.2496","article-title":"Aberrant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma","volume":"217","author":"Baitei","year":"2009","journal-title":"J Pathol"},{"issue":"12","key":"10.1016\/j.cll.2026.06.005_bib102","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.cll.2026.06.005_bib103","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/hed.27025","article-title":"american head and neck society endocrine surgery section and international thyroid oncology group consensus statement on mutational testing in thyroid cancer: defining advanced thyroid cancer and its targeted treatment","volume":"44","author":"Shonka","year":"2022","journal-title":"Head Neck"},{"issue":"5","key":"10.1016\/j.cll.2026.06.005_bib104","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1089\/thy.2018.0716","article-title":"Clinicopathologic features of mismatch repair-deficient anaplastic thyroid carcinomas","volume":"29","author":"Wong","year":"2019","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.cll.2026.06.005_bib105","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1089\/thy.2018.0655","article-title":"Microsatellite instability occurs in a subset of follicular thyroid cancers","volume":"29","author":"Genutis","year":"2019","journal-title":"Thyroid"},{"issue":"10","key":"10.1016\/j.cll.2026.06.005_bib106","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncology"}],"container-title":["Clinics in Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272271226000508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T21:47:45Z","timestamp":1785361665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272271226000508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":106,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0272271226000508"],"URL":"https:\/\/doi.org\/10.1016\/j.cll.2026.06.005","relation":{},"ISSN":["0272-2712"],"issn-type":[{"value":"0272-2712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"This is Your Thyroid on Drugs","name":"articletitle","label":"Article Title"},{"value":"Clinics in Laboratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cll.2026.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}